ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search
  • 2015 American Transplant Congress

    Serum Proteins Are Significantly Upregulated in Patients With Clinical Antibody-Mediated Rejection

    A. Gareau,1 I. Gibson,2 C. Wiebe,1 J. Ho,1 D. Rush,1 P. Nickerson.1

    1Internal Medicine, University of Manitoba, Winnipeg, MB, Canada; 2Pathology, University of Manitoba, Winnipeg, MB, Canada.

    Background: Antibody-mediated rejection (ABMR) is a major pathway associated with late graft loss. Although serum de novo donor-specific HLA antibodies are frequently observed in ABMR,…
  • 2015 American Transplant Congress

    Long-Term Analysis of a Placebo-Controlled Trial of C1-INH for Prevention of Antibody-Mediated Rejection

    A. Vo, J. Choi, J. Kahwaji, D. Puliyanda, A. Peng, R. Villicana, S. Jordan.

    Kidney Transplant, Cedars-Sinai Medical Center, Los Angeles, CA.

    Introduction: Desensitization (DES) strategies focus primarily on antibody reduction using IVIG, rituximab ± PLEX to prevent DSA-induced antibody-mediated rejection (ABMR) and rebound B-cell activity. Recently,…
  • 2015 American Transplant Congress

    Efficacy and Safety of Three Different Treatment Regimen in De Novo Renal Transplant Patients: Month 48 Follow-Up Results of the HERAKLES Trial

    C. Sommerer,1 K. Budde,1 V. Kliem,1 O. Witzke,1 M. Guba,1 J. Jacobi,1 B. Vogt,3 I. Hauser,1 P. Reinke,1 R. Stahl,1 T. Rath,1 M. Porstner,2 D. Baeumer,2 M. Zeier,1 W. Arns,1 F. Lehner.1

    1Herakles Study Group, Germany; 2Novartis Pharma, Nuremberg, Germany; 3Herakles Study Group, Switzerland.

    Aim: To compare safety and efficacy of 3 different immunosuppressive (IS) regimen 4years after renal transplantation (Tx).Methods: 802 patients (pts) were included in this 1year,…
  • 2015 American Transplant Congress

    Validation of the Model for End-Stage Liver Disease Score Criteria in Liver Transplantation for Acute Flare Up of Hepatitis B in Non-Cirrhotic Liver

    W.-C. Lee,1 T.-J. Wu,1 C.-F. Lee,1 R.-S. Soong,1 C.-H. Cheng,1 H.-S. Chou,1 T.-H. Wu,1 K.-M. Chan,1 Y.-C. Wang,1 C.-S. Lee.2

    1Liver and Transplantation Surgery, Chang-Gung Memorial Hospital, Chang-Gung University College of Medicine, Taoyuan, Taiwan; 2Hepatology, Chang-Gung Memorial Hospital, Chang-Gung University College of Medicine, Taoyuan, Taiwan.

    Background: Decision of necessity of urgent liver transplantation for acute flare up of hepatitis B in the patients without cirrhosis is difficult. The MELD score…
  • 2015 American Transplant Congress

    Rational Development of Alloantigen Specific Regulatory T Cell Therapy Requires Insight Into Longevity of Alloimmune Pathways

    J. Ali, M. Negus, E. Bolton, J. Bradley, G. Pettigrew.

    University of Cambridge, Cambridge, United Kingdom.

    IntroductionWe have recently demonstrated that indirect-pathway responses against different alloantigens differ in their strength and longevity; specifically, that indirect responses against MHC class I alloantigen…
  • 2015 American Transplant Congress

    The Forgotten Cell: Renal Fibroblasts Are Activated By Anti-MHC Class I Antibody

    J. Chen, A. Zmijewska, R. Mannon.

    Medicine and Surgery, University of Alabama at Birmingham, Birmingham, AL.

    Chronic antibody-mediated (CAMR) rejection remains a major obstacle in the long term survival of kidney transplants, and is associated in part with interstitial fibrosis (IF)…
  • 2015 American Transplant Congress

    Ischemic Cholangiopathy Following Liver Transplantation from Donation After Circulatory Death Donors: Role of Tissue Plasminogen Activator Flush

    C. Kubal,1 R. Mangus,1 J. Fridell,1 M. Wingler,2 S. Nagai,1 B. Ekser,1 J. Tector.1

    1Department of Surgery, Indiana University, Indianapolis, IN; 2Indiana Organ Procurement Organization, Indianapolis, IN.

    Background: Formation of microthrombi within the peribiliary arterial plexus causing necrosis of biliary epithelium may be responsible for ischemic cholangiopathy (IC) after donation after circulatory…
  • 2015 American Transplant Congress

    Predicting Survival of Deceased Donor Kidneys from Children Under Ten

    W. Parker, J. Thistlethwaite, L. Ross.

    University of Chicago, Chicago, IL.

    Background: The United Network for Organ Sharing (UNOS) has adopted a new allocation algorithm that uses a Kidney Donor Profile Index (KDPI) based on 10…
  • 2015 American Transplant Congress

    Final Results from the BENEFIT-EXT Trial: A 7 Year Follow-Up of Belatacept Treated Patients

    S. Florman,1 J. Medina Pestana,2 M. Rial,3 L. Rostaing,4 D. Kuypers,5 F. Mühlbacher,6 M. Polinsky,7 U. Meier-Kriesche,7 J. Grinyó,8 A. Durrbach.9

    1Mt Sinai Med Ctr, NY; 2Hosp do Rim e Hipertensão, Sao Paulo, Brazil; 3Inst de Nefrologia, Buenos Aires, Argentina; 4Univ Hospital, Toulouse, France; 5Univ Hospital Leuven, Leuven, Belgium; 6Vienna Transplantation Ctr, Vienna, Austria; 7BMS, Lawrenceville; 8Univ Hosp Bellvitge, Barcelona, Spain; 9Univ Hosp of Bicêtre, Villejuif, France.

    Background: At 3 and 5yrs post-transplant, BENEFIT-EXT showed a renal function benefit and consistent safety in belatacept (bela) treated pts vs cyclosporine (CsA). Final 7…
  • 2015 American Transplant Congress

    Eomes-Expressing CD8+ T Cells and Th17 Cells Mediate Costimulatory Blockade-Resistant Allograft Rejection in Mice

    M. Sabet-Baktach,1 E. Eggenhofer,1 P. Renner,1 M. Lantow,1 H. Schlitt,1 E. Geissler,1 A. Kroemer.1,2

    1Department of Surgery, University Hospital Regensburg, Regensburg, Germany; 2Georgetown Transplant Institute, Georgetown Transplant Institute, Washington, DC.

    The etiology of costimulatory blockade-resistant allograft rejection remains unclear. Therefore, the purpose of this study was to evaluate the responsiveness of distinct CD4+ and CD8+…
  • « Previous Page
  • 1
  • …
  • 53
  • 54
  • 55
  • 56
  • 57
  • …
  • 170
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences